CTMX
CytomX Therapeutics, Inc.$4.63-0.14 (-3.03%)Prev Close$4.78·MCap$854.0M·P/E—·Vol2.11M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
8
$1.91M
◆
Net Activity
Net Seller
$1.91M
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at CytomX Therapeutics, Inc. (CTMX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 8 insider sales totaling $1.91M. The most recent insider transaction was by BELVIN MARCIA (officer: SVP, Chief Scientific Officer), who sold $202.3K worth of shares on Mar 19, 2026. CytomX Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $854.0M.
CTMX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | BELVIN MARCIA | officer: SVP, Chief Scientific Officer | Sell | 31,492 | $6.42 | $202.3K | 300,760 |
| Mar 19, 2026 | Chu Yu-Waye | officer: Chief Medical Officer | Sell | 21,279 | $6.42 | $136.7K | 189,446 |
| Mar 19, 2026 | McCarthy Sean A. | director, officer: CEO | Sell | 118,969 | $6.42 | $764.1K | 1,078,922 |
| Mar 19, 2026 | Ogden Christopher | officer: Chief Financial Officer | Sell | 19,323 | $6.42 | $124.1K | 296,948 |
| Nov 6, 2025 | McCarthy Sean A. | CEO | Sell | 101,793 | $4.54 | $461.9K | 0 |
| Jun 13, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 13,884 | $2.69 | $37.3K | 0 |
| Jun 13, 2025 | McCarthy Sean A. | CEO | Sell | 55,511 | $2.69 | $149.3K | 0 |
| Jun 13, 2025 | Ogden Christopher | Chief Financial Officer | Sell | 12,255 | $2.72 | $33.4K | 0 |
| Mar 18, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 19,512 | $0.60 | $11.7K | 0 |
| Mar 18, 2025 | Chu Yu-Waye | Chief Medical Officer | Sell | 4,025 | $0.60 | $2.4K | 0 |
| Mar 18, 2025 | McCarthy Sean A. | CEO | Sell | 37,656 | $0.60 | $22.6K | 0 |
| Mar 18, 2025 | Ogden Christopher | Chief Financial Officer | Sell | 8,551 | $0.60 | $5.1K | 0 |
| Mar 18, 2025 | ROWLAND LLOYD A | General Counsel | Sell | 10,203 | $0.60 | $6.1K | 0 |
| Aug 20, 2024 | Landau Jeffrey B | Chief Business Officer | Sell | 4,181 | $1.23 | $5.1K | 0 |
| Aug 20, 2024 | McCarthy Sean A. | CEO | Sell | 13,898 | $1.23 | $17.1K | 0 |
| Aug 20, 2024 | Ogden Christopher | Chief Financial Officer | Sell | 1,984 | $1.23 | $2.4K | 0 |
| Mar 19, 2024 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 12,795 | $2.09 | $26.7K | 0 |
| Mar 19, 2024 | Landau Jeffrey B | Chief Business Officer | Sell | 6,562 | $2.09 | $13.7K | 0 |
| Mar 19, 2024 | McCarthy Sean A. | CEO | Sell | 20,223 | $2.09 | $42.2K | 0 |
| Mar 19, 2024 | Ogden Christopher | SVP, Finance and Accounting | Sell | 2,971 | $2.09 | $6.2K | 0 |
| Mar 19, 2024 | ROWLAND LLOYD A | General Counsel | Sell | 5,268 | $2.09 | $11.0K | 0 |
| Dec 20, 2023 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 4,077 | $1.38 | $5.6K | 0 |
| Dec 20, 2023 | McCarthy Sean A. | CEO | Sell | 13,551 | $1.38 | $18.7K | 0 |
| Dec 20, 2023 | Ogden Christopher | SVP, Finance and Accounting | Sell | 1,990 | $1.38 | $2.7K | 0 |
| Sep 20, 2023 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 4,119 | $1.30 | $5.4K | 0 |
| Sep 20, 2023 | McCarthy Sean A. | CEO | Sell | 14,601 | $1.30 | $19.0K | 0 |
| Sep 20, 2023 | ROWLAND LLOYD A | General Counsel | Sell | 5,486 | $1.30 | $7.1K | 0 |
| Mar 29, 2023 | Jones Elaine V | Director | Buy | 5,000 | $1.55 | $7.8K | 0 |
| Mar 16, 2023 | Campoy Carlos | Chief Financial Officer | Sell | 1,748 | $1.98 | $3.5K | 0 |
| Mar 16, 2023 | Landau Jeffrey B | Chief Financial Officer | Sell | 1,477 | $1.98 | $2.9K | 0 |
| Mar 16, 2023 | McCarthy Sean A. | CEO | Sell | 7,121 | $1.88 | $13.4K | 0 |
| Mar 16, 2023 | Ogden Christopher | SVP, Finance and Accounting | Sell | 516 | $1.98 | $1.0K | 0 |
| Mar 16, 2023 | Peterson Amy C. | EVP, Chief Development Officer | Sell | 4,257 | $1.98 | $8.4K | 0 |
| Mar 16, 2023 | ROWLAND LLOYD A | General Counsel | Sell | 2,037 | $1.98 | $4.0K | 0 |
| Jul 19, 2022 | Campoy Carlos | Chief Financial Officer | Sell | 3,949 | $1.42 | $5.6K | 0 |
| Jul 19, 2022 | Landau Jeffrey B | Chief Business Officer | Sell | 4,206 | $1.42 | $6.0K | 0 |
| Jul 19, 2022 | McCarthy Sean A. | President and CEO | Sell | 14,911 | $1.42 | $21.2K | 0 |
| Jul 19, 2022 | Peterson Amy C. | EVP, Chief Development Officer | Sell | 7,463 | $1.42 | $10.6K | 0 |
| Jul 19, 2022 | ROWLAND LLOYD A | General Counsel | Sell | 5,602 | $1.42 | $8.0K | 0 |
| Jun 16, 2021 | McCarthy Sean A. | President and CEO | Sell | 100,000 | $7.04 | $704.5K | 0 |
| Mar 31, 2021 | McCarthy Sean A. | President and CEO | Sell | 100,000 | $7.49 | $749.5K | 0 |
CTMX Insider Buying Activity
The following table shows recent insider purchases of CytomX Therapeutics, Inc. (CTMX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 29, 2023 | Jones Elaine V | Director | Buy | 5,000 | $1.55 | $7.8K | 0 |
CTMX Insider Selling Activity
The following table shows recent insider sales of CytomX Therapeutics, Inc. (CTMX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | BELVIN MARCIA | officer: SVP, Chief Scientific Officer | Sell | 31,492 | $6.42 | $202.3K | 300,760 |
| Mar 19, 2026 | Chu Yu-Waye | officer: Chief Medical Officer | Sell | 21,279 | $6.42 | $136.7K | 189,446 |
| Mar 19, 2026 | McCarthy Sean A. | director, officer: CEO | Sell | 118,969 | $6.42 | $764.1K | 1,078,922 |
| Mar 19, 2026 | Ogden Christopher | officer: Chief Financial Officer | Sell | 19,323 | $6.42 | $124.1K | 296,948 |
| Nov 6, 2025 | McCarthy Sean A. | CEO | Sell | 101,793 | $4.54 | $461.9K | 0 |
| Jun 13, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 13,884 | $2.69 | $37.3K | 0 |
| Jun 13, 2025 | McCarthy Sean A. | CEO | Sell | 55,511 | $2.69 | $149.3K | 0 |
| Jun 13, 2025 | Ogden Christopher | Chief Financial Officer | Sell | 12,255 | $2.72 | $33.4K | 0 |
| Mar 18, 2025 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 19,512 | $0.60 | $11.7K | 0 |
| Mar 18, 2025 | Chu Yu-Waye | Chief Medical Officer | Sell | 4,025 | $0.60 | $2.4K | 0 |
| Mar 18, 2025 | McCarthy Sean A. | CEO | Sell | 37,656 | $0.60 | $22.6K | 0 |
| Mar 18, 2025 | Ogden Christopher | Chief Financial Officer | Sell | 8,551 | $0.60 | $5.1K | 0 |
| Mar 18, 2025 | ROWLAND LLOYD A | General Counsel | Sell | 10,203 | $0.60 | $6.1K | 0 |
| Aug 20, 2024 | Landau Jeffrey B | Chief Business Officer | Sell | 4,181 | $1.23 | $5.1K | 0 |
| Aug 20, 2024 | McCarthy Sean A. | CEO | Sell | 13,898 | $1.23 | $17.1K | 0 |
| Aug 20, 2024 | Ogden Christopher | Chief Financial Officer | Sell | 1,984 | $1.23 | $2.4K | 0 |
| Mar 19, 2024 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 12,795 | $2.09 | $26.7K | 0 |
| Mar 19, 2024 | Landau Jeffrey B | Chief Business Officer | Sell | 6,562 | $2.09 | $13.7K | 0 |
| Mar 19, 2024 | McCarthy Sean A. | CEO | Sell | 20,223 | $2.09 | $42.2K | 0 |
| Mar 19, 2024 | Ogden Christopher | SVP, Finance and Accounting | Sell | 2,971 | $2.09 | $6.2K | 0 |
| Mar 19, 2024 | ROWLAND LLOYD A | General Counsel | Sell | 5,268 | $2.09 | $11.0K | 0 |
| Dec 20, 2023 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 4,077 | $1.38 | $5.6K | 0 |
| Dec 20, 2023 | McCarthy Sean A. | CEO | Sell | 13,551 | $1.38 | $18.7K | 0 |
| Dec 20, 2023 | Ogden Christopher | SVP, Finance and Accounting | Sell | 1,990 | $1.38 | $2.7K | 0 |
| Sep 20, 2023 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 4,119 | $1.30 | $5.4K | 0 |
| Sep 20, 2023 | McCarthy Sean A. | CEO | Sell | 14,601 | $1.30 | $19.0K | 0 |
| Sep 20, 2023 | ROWLAND LLOYD A | General Counsel | Sell | 5,486 | $1.30 | $7.1K | 0 |
| Mar 16, 2023 | Campoy Carlos | Chief Financial Officer | Sell | 1,748 | $1.98 | $3.5K | 0 |
| Mar 16, 2023 | Landau Jeffrey B | Chief Financial Officer | Sell | 1,477 | $1.98 | $2.9K | 0 |
| Mar 16, 2023 | McCarthy Sean A. | CEO | Sell | 7,121 | $1.88 | $13.4K | 0 |
| Mar 16, 2023 | Ogden Christopher | SVP, Finance and Accounting | Sell | 516 | $1.98 | $1.0K | 0 |
| Mar 16, 2023 | Peterson Amy C. | EVP, Chief Development Officer | Sell | 4,257 | $1.98 | $8.4K | 0 |
| Mar 16, 2023 | ROWLAND LLOYD A | General Counsel | Sell | 2,037 | $1.98 | $4.0K | 0 |
| Jul 19, 2022 | Campoy Carlos | Chief Financial Officer | Sell | 3,949 | $1.42 | $5.6K | 0 |
| Jul 19, 2022 | Landau Jeffrey B | Chief Business Officer | Sell | 4,206 | $1.42 | $6.0K | 0 |
| Jul 19, 2022 | McCarthy Sean A. | President and CEO | Sell | 14,911 | $1.42 | $21.2K | 0 |
| Jul 19, 2022 | Peterson Amy C. | EVP, Chief Development Officer | Sell | 7,463 | $1.42 | $10.6K | 0 |
| Jul 19, 2022 | ROWLAND LLOYD A | General Counsel | Sell | 5,602 | $1.42 | $8.0K | 0 |
| Jun 16, 2021 | McCarthy Sean A. | President and CEO | Sell | 100,000 | $7.04 | $704.5K | 0 |
| Mar 31, 2021 | McCarthy Sean A. | President and CEO | Sell | 100,000 | $7.49 | $749.5K | 0 |
CTMX Insiders
Similar Stocks to CTMX
VRTX
Vertex Pharmaceuticals Incorporated
$457.85-0.04%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$739.02+0.21%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$317.52+2.03%
$42.07B
INSM
Insmed Incorporated
$140.27-2.59%
$30.07B
UTHR
United Therapeutics Corporation
$528.90+0.36%
$23.50B
MRNA
Moderna, Inc.
$52.39+0.04%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.60-0.72%
$20.08B
RPRX
Royalty Pharma plc
$45.34-0.41%
$19.56B